Advancing CAR-T Therapies with Real-World Clinical Data to Drive Next- Generation Development
4:25 pm - Wednesday 25th February 2026
- Share up-to-date clinical data from the ongoing CAR-T program in T-cell leukaemia
- Discuss the latest development from OneChain’s next-generation CAR-T products across hematologic malignancies and solid tumours
- Explore advantages and opportunities with OneChain’s allogeneic iPSC-derived gamma delta T-cell platform
New Data
